A randomized phase III trial investigating platinum and taxane chemotherapy in metastatic castration resistant prostate cancer (mCRPC) patients with alterations in DNA damage response (DDR) genes (OPTION-DDR) CCTG-PR-25 NCT06439225.

Authors: Michael Paul Kolinsky, Kim N. Chi, Sebastien J. Hotte, Michael Donald Brundage, Michael Ong, David Boren, M. Neil Reaume, Alexander William Wyatt, Wendy R. Parulekar, Keyue Ding, Mariam Jafri

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps5122

Source: Full article

---

Abstract

TPS5122